| Charles Bellamy, MD | |
|
2139 Auburn Ave, Cincinnati, OH 45219-2906 | |
| (513) 585-2422 | |
| (513) 585-3245 |
| Full Name | Charles Bellamy |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 39 Years |
| Location | 2139 Auburn Ave, Cincinnati, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043218803 | NPI | - | NPPES |
| 0754447 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 35058388 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christ Hospital | Cincinnati, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pain Management Associates Llc | 1456254812 | 15 |
| Anesthesia Associates Of Cincinnati, Inc | 4789598509 | 115 |
| Pain Management Associates Llc | 1456254812 | 15 |
News Archive
A research team led by Prof. Dr. Winfried Römer and Dr. Elias Hobeika from the University of Freiburg and the University Medical Center in Ulm has discovered a mechanism with which bacteria activate white blood cells and attack an organism's immune system. The scientists recently published the results in the journal Science Signaling.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that it received a Manufacturing Accreditation delivered by the French National Agency for Drug Safety. The status has been received for its cell therapy production site in Besançon, France.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has established the new brand identity "Right Where You Need Us," which reflects various transformation initiatives focused on meeting the diverse requirements of the Company's clients.
A University of Southampton Professor, in collaboration with colleagues at the BC Cancer Agency Research Centre, have discovered a novel way of killing cancer cells. The research, recently published in the journal Cell, has found a new potential treatment for cancer, which leaves the body's healthy cells undamaged, unlike traditional therapies such as radiotherapy.
KineMed Inc. today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches in metabolic disease, in particular Type II diabetes.
› Verified 7 days ago
| Entity Name | Anesthesia Associates Of Cincinnati, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316945173 PECOS PAC ID: 4789598509 Enrollment ID: O20031117000374 |
News Archive
A research team led by Prof. Dr. Winfried Römer and Dr. Elias Hobeika from the University of Freiburg and the University Medical Center in Ulm has discovered a mechanism with which bacteria activate white blood cells and attack an organism's immune system. The scientists recently published the results in the journal Science Signaling.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that it received a Manufacturing Accreditation delivered by the French National Agency for Drug Safety. The status has been received for its cell therapy production site in Besançon, France.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has established the new brand identity "Right Where You Need Us," which reflects various transformation initiatives focused on meeting the diverse requirements of the Company's clients.
A University of Southampton Professor, in collaboration with colleagues at the BC Cancer Agency Research Centre, have discovered a novel way of killing cancer cells. The research, recently published in the journal Cell, has found a new potential treatment for cancer, which leaves the body's healthy cells undamaged, unlike traditional therapies such as radiotherapy.
KineMed Inc. today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches in metabolic disease, in particular Type II diabetes.
› Verified 7 days ago
| Entity Name | Pain Management Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699775536 PECOS PAC ID: 1456254812 Enrollment ID: O20040202000116 |
News Archive
A research team led by Prof. Dr. Winfried Römer and Dr. Elias Hobeika from the University of Freiburg and the University Medical Center in Ulm has discovered a mechanism with which bacteria activate white blood cells and attack an organism's immune system. The scientists recently published the results in the journal Science Signaling.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that it received a Manufacturing Accreditation delivered by the French National Agency for Drug Safety. The status has been received for its cell therapy production site in Besançon, France.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has established the new brand identity "Right Where You Need Us," which reflects various transformation initiatives focused on meeting the diverse requirements of the Company's clients.
A University of Southampton Professor, in collaboration with colleagues at the BC Cancer Agency Research Centre, have discovered a novel way of killing cancer cells. The research, recently published in the journal Cell, has found a new potential treatment for cancer, which leaves the body's healthy cells undamaged, unlike traditional therapies such as radiotherapy.
KineMed Inc. today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches in metabolic disease, in particular Type II diabetes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles Bellamy, MD 2139 Auburn Ave, Cincinnati, OH 45219-2906 Ph: (513) 585-2422 | Charles Bellamy, MD 2139 Auburn Ave, Cincinnati, OH 45219-2906 Ph: (513) 585-2422 |
News Archive
A research team led by Prof. Dr. Winfried Römer and Dr. Elias Hobeika from the University of Freiburg and the University Medical Center in Ulm has discovered a mechanism with which bacteria activate white blood cells and attack an organism's immune system. The scientists recently published the results in the journal Science Signaling.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that it received a Manufacturing Accreditation delivered by the French National Agency for Drug Safety. The status has been received for its cell therapy production site in Besançon, France.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has established the new brand identity "Right Where You Need Us," which reflects various transformation initiatives focused on meeting the diverse requirements of the Company's clients.
A University of Southampton Professor, in collaboration with colleagues at the BC Cancer Agency Research Centre, have discovered a novel way of killing cancer cells. The research, recently published in the journal Cell, has found a new potential treatment for cancer, which leaves the body's healthy cells undamaged, unlike traditional therapies such as radiotherapy.
KineMed Inc. today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches in metabolic disease, in particular Type II diabetes.
› Verified 7 days ago
Alexander Topala, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman St, Mail Location 0796, Cincinnati, OH 45219 Phone: 513-584-1000 | |
Eli Cianciolo, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4805 Montgomery Rd, Suite 210, Cincinnati, OH 45212 Phone: 513-791-6400 Fax: 513-791-5306 | |
Angel Joshua Pagan, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 234 Goodman St, Cincinnati, OH 45219 Phone: 513-558-6356 | |
Dave Wright, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2139 Auburn Ave, Cincinnati, OH 45219 Phone: 513-585-2422 Fax: 513-585-3245 | |
Robert S Jacob, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2139 Auburn Ave, Cincinnati, OH 45219 Phone: 513-672-3309 Fax: 513-672-3323 | |
Mr. Kun Lee, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 4777 E Galbraith Rd, Cincinnati, OH 45236 Phone: 513-686-3000 | |
Nalini Tandon, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 7500 State Rd, Anethesia Intensive Care Consultants Inc, Cincinnati, OH 45255 Phone: 859-341-7246 Fax: 859-341-7867 |